138 related articles for article (PubMed ID: 37404077)
1. Nanoparticles Hitchhike on Monocytes for Glioblastoma Treatment after Low-Dose Radiotherapy.
Kuang J; Rao ZY; Zheng DW; Kuang D; Huang QX; Pan T; Li H; Zeng X; Zhang XZ
ACS Nano; 2023 Jul; 17(14):13333-13347. PubMed ID: 37404077
[TBL] [Abstract][Full Text] [Related]
2. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities.
Wang G; Zhong K; Wang Z; Zhang Z; Tang X; Tong A; Zhou L
Front Immunol; 2022; 13():964898. PubMed ID: 35967394
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.
Rao G; Latha K; Ott M; Sabbagh A; Marisetty A; Ling X; Zamler D; Doucette TA; Yang Y; Kong LY; Wei J; Fuller GN; Benavides F; Sonabend AM; Long J; Li S; Curran M; Heimberger AB
Clin Cancer Res; 2020 Sep; 26(17):4699-4712. PubMed ID: 32554515
[TBL] [Abstract][Full Text] [Related]
6. A Combined Approach Employing Chlorotoxin-Nanovectors and Low Dose Radiation To Reach Infiltrating Tumor Niches in Glioblastoma.
Tamborini M; Locatelli E; Rasile M; Monaco I; Rodighiero S; Corradini I; Franchini MC; Passoni L; Matteoli M
ACS Nano; 2016 Feb; 10(2):2509-20. PubMed ID: 26745323
[TBL] [Abstract][Full Text] [Related]
7. Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis.
Feng X; Szulzewsky F; Yerevanian A; Chen Z; Heinzmann D; Rasmussen RD; Alvarez-Garcia V; Kim Y; Wang B; Tamagno I; Zhou H; Li X; Kettenmann H; Ransohoff RM; Hambardzumyan D
Oncotarget; 2015 Jun; 6(17):15077-94. PubMed ID: 25987130
[TBL] [Abstract][Full Text] [Related]
8. Brain-targeted antigen-generating nanoparticles improve glioblastoma prognosis.
Wang W; Zhang M; Zhang Q; Mohammadniaei M; Shen J; Sun Y
J Control Release; 2022 Dec; 352():399-410. PubMed ID: 36309097
[TBL] [Abstract][Full Text] [Related]
9. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy.
Khan F; Pang L; Dunterman M; Lesniak MS; Heimberger AB; Chen P
J Clin Invest; 2023 Jan; 133(1):. PubMed ID: 36594466
[TBL] [Abstract][Full Text] [Related]
10. Intravital 2-photon imaging reveals distinct morphology and infiltrative properties of glioblastoma-associated macrophages.
Chen Z; Ross JL; Hambardzumyan D
Proc Natl Acad Sci U S A; 2019 Jul; 116(28):14254-14259. PubMed ID: 31235603
[TBL] [Abstract][Full Text] [Related]
11. Chlorotoxin modified morusin-PLGA nanoparticles for targeted glioblastoma therapy.
Agarwal S; Mohamed MS; Mizuki T; Maekawa T; Sakthi Kumar D
J Mater Chem B; 2019 Oct; 7(39):5896-5919. PubMed ID: 31423502
[TBL] [Abstract][Full Text] [Related]
12. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
[TBL] [Abstract][Full Text] [Related]
13. Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma.
Wu H; Guo C; Wang C; Xu J; Zheng S; Duan J; Li Y; Bai H; Xu Q; Ning F; Wang F; Yang Q
Cancer Sci; 2023 Jun; 114(6):2609-2621. PubMed ID: 36853018
[TBL] [Abstract][Full Text] [Related]
14. PTN-PTPRZ1 signaling axis blocking mediates tumor microenvironment remodeling for enhanced glioblastoma treatment.
Yang M; Wang B; Yin Y; Ma X; Tang L; Zhang Y; Fan Q; Yin T; Wang Y
J Control Release; 2023 Jan; 353():63-76. PubMed ID: 36402232
[TBL] [Abstract][Full Text] [Related]
15. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
16. Monocyte-mediated chemotherapy drug delivery in glioblastoma.
Wang C; Li K; Li T; Chen Z; Wen Y; Liu X; Jia X; Zhang Y; Xu Y; Han M; Komatsu N; Zhao L; Chen X
Nanomedicine (Lond); 2018 Jan; 13(2):157-178. PubMed ID: 29173008
[TBL] [Abstract][Full Text] [Related]
17. Exploring Monocytes-Macrophages in Immune Microenvironment of Glioblastoma for the Design of Novel Therapeutic Strategies.
Caverzán MD; Beaugé L; Oliveda PM; Cesca González B; Bühler EM; Ibarra LE
Brain Sci; 2023 Mar; 13(4):. PubMed ID: 37190507
[TBL] [Abstract][Full Text] [Related]
18. Revealing and Harnessing Tumour-Associated Microglia/Macrophage Heterogeneity in Glioblastoma.
Pires-Afonso Y; Niclou SP; Michelucci A
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31973030
[No Abstract] [Full Text] [Related]
19. Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.
Stafford JH; Hirai T; Deng L; Chernikova SB; Urata K; West BL; Brown JM
Neuro Oncol; 2016 Jun; 18(6):797-806. PubMed ID: 26538619
[TBL] [Abstract][Full Text] [Related]
20. Immune Microenvironment in Glioblastoma Subtypes.
Chen Z; Hambardzumyan D
Front Immunol; 2018; 9():1004. PubMed ID: 29867979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
